These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 31436251)
1. Prevalence of Yu Y; Zhang Q; Zhang J; Lu S J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251 [TBL] [Abstract][Full Text] [Related]
2. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas. Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818 [TBL] [Abstract][Full Text] [Related]
3. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer. Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211 [TBL] [Abstract][Full Text] [Related]
4. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values. Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721 [TBL] [Abstract][Full Text] [Related]
5. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer. Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039 [TBL] [Abstract][Full Text] [Related]
6. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer. Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638 [TBL] [Abstract][Full Text] [Related]
7. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer. Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577 [TBL] [Abstract][Full Text] [Related]
8. Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas. Liang X; Li Q; Xu B; Hu S; Wang Q; Li Y; Zong Y; Zhang S; Li C Int J Clin Oncol; 2019 Sep; 24(9):1061-1068. PubMed ID: 31065835 [TBL] [Abstract][Full Text] [Related]
9. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738 [TBL] [Abstract][Full Text] [Related]
10. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification. Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494 [TBL] [Abstract][Full Text] [Related]
11. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952 [TBL] [Abstract][Full Text] [Related]
12. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443 [TBL] [Abstract][Full Text] [Related]
13. Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study. Shi M; Ma J; Feng M; Liang L; Chen H; Wang T; Xie Z Cancer Genet; 2021 Aug; 256-257():62-67. PubMed ID: 33905998 [TBL] [Abstract][Full Text] [Related]
14. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659 [TBL] [Abstract][Full Text] [Related]
15. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. Zheng D; Wang R; Ye T; Yu S; Hu H; Shen X; Li Y; Ji H; Sun Y; Chen H Oncotarget; 2016 Jul; 7(27):41691-41702. PubMed ID: 27223439 [TBL] [Abstract][Full Text] [Related]
16. MET Exon 14 Skipping in Non-Small Cell Lung Cancer. Heist RS; Shim HS; Gingipally S; Mino-Kenudson M; Le L; Gainor JF; Zheng Z; Aryee M; Xia J; Jia P; Jin H; Zhao Z; Pao W; Engelman JA; Iafrate AJ Oncologist; 2016 Apr; 21(4):481-6. PubMed ID: 27022036 [TBL] [Abstract][Full Text] [Related]
17. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Rotow JK; Gui P; Wu W; Raymond VM; Lanman RB; Kaye FJ; Peled N; Fece de la Cruz F; Nadres B; Corcoran RB; Yeh I; Bastian BC; Starostik P; Newsom K; Olivas VR; Wolff AM; Fraser JS; Collisson EA; McCoach CE; Camidge DR; Pacheco J; Bazhenova L; Li T; Bivona TG; Blakely CM Clin Cancer Res; 2020 Jan; 26(2):439-449. PubMed ID: 31548343 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Vuong HG; Ho ATN; Altibi AMA; Nakazawa T; Katoh R; Kondo T Lung Cancer; 2018 Sep; 123():76-82. PubMed ID: 30089599 [TBL] [Abstract][Full Text] [Related]
19. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593 [TBL] [Abstract][Full Text] [Related]
20. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma. Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]